Skip to main navigation
Skip to content
Skip to content
PDL Logo Blue Green
  • About PDL
    • Leadership
  • Equity Investments
    • Noden
    • Noden’s Products
    • Lensar
    • LENSAR Product
  • Alternative Financings
    • Portfolio of Assets
    • On-Going Transactions
    • Concluded Transactions
  • Investor Relations
  • News
  • Contact
  • About PDL
    • Management
  • Equity Investments
    • Noden
    • Noden’s Products
    • Lensar
    • LENSAR Product
  • Alternative Financings
    • Portfolio of Assets
    • On-Going Transactions
    • Concluded Transactions
  • Investor Relations
  • News
  • Contact

Press Releases

PDL  > Investor Relations > Press Releases

Press Releases

  • Summary TogglePDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024
    INCLINE VILLAGE, Nev. , Dec. 13, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of its
    Dec 13, 2019
  • Summary TogglePDL BioPharma Announces Completion of Strategic Review Process
    Will Pursue Monetization of its Assets and Optimal Means of Returning Proceeds to Shareholders; Will Cease Making Additional Strategic Acquisitions and Investments Board Authorizes Repurchase Program to Acquire up to $200 Million of Outstanding PDL Stock and Convertible Notes Conference Call at
    Dec 9, 2019
  • Summary TogglePDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
    INCLINE VILLAGE, Nev. , Dec. 3, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM) on its recent achievement of two major regulatory and clinical milestones with its lead product candidate Amphora ®
    Dec 3, 2019
  • Summary TogglePDL BioPharma Reaffirms Commitment To Shareholder Value Creation
    Responds to Escalation of Engine Capital's Public Campaign INCLINE VILLAGE, Nev. , Nov. 14, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today issued the following statement in response to Engine Capital LP's ("Engine") escalation of its public campaign
    Nov 14, 2019
  • Summary TogglePDL BioPharma Reports 2019 Third Quarter Financial Results
    Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets Conference call at 4:30 p.m. Eastern time today INCLINE VILLAGE, Nev. , Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for
    Nov 6, 2019
  • Summary TogglePDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019
    INCLINE VILLAGE, Nev. , Oct. 30, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter 2019 financial results for the period ended September 30, 2019 , on Wednesday, November 6, 2019 , after market close.
    Oct 30, 2019
  • Summary TogglePDL BioPharma Responds to Letter from Engine Capital
    INCLINE VILLAGE, Nev. , Oct. 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that Harold E. Selick , Ph.D., Chairman of the Board of Directors of PDL BioPharma , has sent the following letter to Engine Capital, LP .
    Oct 24, 2019
  • Summary TogglePDL BioPharma to Participate in the 2019 Cantor Fitzgerald Global Healthcare Conference
      INCLINE VILLAGE, Nev. , Sept. 26, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019 ,
    Sep 26, 2019
  • Summary TogglePDL BioPharma Announces Private Exchange of Approximately $86.1 Million of Convertible Notes Due 2024
    INCLINE VILLAGE, Nev. , Sept. 12, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated transactions to exchange approximately $86.1 million in aggregate principal amount of its 2.75% Convertible
    Sep 12, 2019
  • Summary TogglePDL BioPharma Announces Favorable Decision in Wellstat Diagnostics Litigation
    INCLINE VILLAGE, Nev. , Sept. 11, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that the Supreme Court of New York , County of New York , Commercial Division, issued its decision today in PDL's previously disclosed litigation related to defaults by
    Sep 11, 2019
  • Summary TogglePDL BioPharma Reports 2019 Second Quarter Financial Results
    INCLINE VILLAGE, Nev. , Aug. 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2019 : Second Quarter and Recent Financial Highlights Generally Accepted Accounting Principles ("GAAP") net loss
    Aug 7, 2019
  • Summary TogglePDL BioPharma to Announce Second Quarter 2019 Financial Results on August 7, 2019
    INCLINE VILLAGE, Nev. , July 31, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its second quarter 2019 financial results for the period ended June 30, 2019 , on Wednesday, August 7, 2019 , after market close.
    Jul 31, 2019
  • Summary TogglePDL BioPharma Announces Departure of CFO
    INCLINE VILLAGE, Nev. , June 25, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the resignation of Chief Financial Officer, Peter Garcia , who will be leaving the Company effective August 15, 2019 . He will continue in his role through the filing
    Jun 25, 2019
  • Summary ToggleNatasha A. Hernday Elected to PDL BioPharma's Board of Directors
    INCLINE VILLAGE, Nev. , June 24, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019 , the Company's stockholders elected Natasha A. Hernday to the Company's Board of Directors.
    Jun 24, 2019
  • Summary ToggleEvofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
    - Strategic financing to advance the commercialization of Evofem's lead asset, Amphora® - SAN DIEGO and INCLINE VILLAGE, Nev. , June 10, 2019 /PRNewswire/ --  Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc.
    Jun 10, 2019

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Tax Information
    • SEC Filings
    • Stock Information
    • Contact Us

    Current Alternative Investments

    image

    Learn More

     

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • RSS
    • Print
    • Share
    • Search
    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

PDL Logo White Fill

  • Terms of Use
  • Sitemap
© Copyright 2019 PDL BioPHARMA. All Rights Reserved.